Investors urged to participate in Lantheus Holdings, Inc. (LNTH) securities fraud class action lawsuit

A securities fraud class action lawsuit has been filed by Glancy Prongay & Murray LLP against Lantheus Holdings, Inc. The lawsuit pertains to investors who bought or obtained LNTH securities between February 26, 2025, and August 5, 2025. Allegations have been made that Lantheus provided false and misleading information about its business, operations, and future prospects, particularly regarding its key product, Pylarify. Investors have until November 10, 2025, to file a lead plaintiff motion.

Lantheus Holdings, Inc. (NASDAQ: LNTH) is a global company specializing in diagnostic and therapeutic products. The securities fraud class action lawsuit brought forth by Glancy Prongay & Murray LLP accuses Lantheus of disseminating inaccurate information about its business, operations, and prospects, particularly concerning its essential Radiopharmaceutical Oncology product, Pylarify. The class-action lawsuit covers the period from February 26, 2025, to August 5, 2025.

The lawsuit claims that Lantheus misrepresented the competitive standing of Pylarify to investors. It is alleged that Lantheus lacked the capability to evaluate the pricing and competitive landscape of Pylarify accurately, leading to a flawed understanding of the product’s market position. Moreover, the company failed to disclose that its price increase early in 2025, despite the previous year’s price erosion, created favorable conditions for competitive pricing to thrive, putting at risk Pylarify’s pricing, revenue, and overall growth opportunities.

On August 6, 2025, Lantheus reported disappointing results for Pylarify, which had decreased by 8.3% year-over-year. The company also significantly revised its growth forecasts for the fiscal year 2025. The disclosure resulted in a substantial drop in Lantheus’ stock price, plummeting from $72.83 per share on August 5, 2025, to $51.87 per share on August 6, 2025, representing a one-day decline of approximately 28.8%.

Investors who bought or acquired Lantheus securities within the specified class period should consider reaching out to Glancy Prongay & Murray LLP to assess their eligibility for the lawsuit. The deadline to submit a lead plaintiff motion is November 10, 2025. It is important to note that investors do not need to be appointed as a lead plaintiff to participate in any potential recovery, and they can opt to be absentee class members if they prefer not to take action.

Glancy Prongay & Murray LLP is a reputable firm with expertise in shareholder rights litigation, dedicated to helping investors recover losses and holding corporate executives accountable for their actions. The firm aims to secure compensation for investors who suffered financial setbacks due to false or misleading statements.